CELC
NASD Celcuity Inc.$81.34 ↑ +1.70 (+2.13%) Trading Up from the previous close of $79.64
- YTD change
- -18.45%
- vs 20-day SMA
- -5.55%
- vs 200-day SMA
- -22.50%
Price ranges
Price & Performance
-28.63 (-26.44%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 46.1% away from all-time highs of $151.02
- CELC is down 18% since the beginning of the year
- CELC is up 56% over the past 12 months
- CELC is down 8% over the past 1 month
- 24% of all CELC investors are betting against CELC
CELC reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +52.9%.
- Previous minute
- +$0.00
- Last hour
- -$0.18
- Last 5 days
- -3.17%
- vs 8-day SMA
- -0.22%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
